Share on StockTwits

Seattle Genetics (NASDAQ:SGEN) CEO Clay B. Siegall unloaded 2,700 shares of the company’s stock on the open market in a transaction dated Monday, August 11th. The shares were sold at an average price of $40.05, for a total transaction of $108,135.00. Following the sale, the chief executive officer now directly owns 525,217 shares in the company, valued at approximately $21,034,941. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Seattle Genetics (NASDAQ:SGEN) traded up 2.31% on Wednesday, hitting $41.60. The stock had a trading volume of 902,889 shares. Seattle Genetics has a 1-year low of $32.35 and a 1-year high of $55.99. The stock’s 50-day moving average is $36.9 and its 200-day moving average is $41.30. The company’s market cap is $5.135 billion.

Seattle Genetics (NASDAQ:SGEN) last posted its quarterly earnings results on Thursday, July 31st. The company reported ($0.14) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.23) by $0.09. The company had revenue of $68.30 million for the quarter, compared to the consensus estimate of $65.04 million. During the same quarter last year, the company posted ($0.06) earnings per share. Seattle Genetics’s revenue was down 7.2% compared to the same quarter last year. On average, analysts predict that Seattle Genetics will post $-0.81 earnings per share for the current fiscal year.

Seattle Genetics, Inc is biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.